Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. (Q53418146)

14 May 2018

title

Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. (English)

1 reference

14 May 2018

1 reference

3

Donna Neuberg

1 reference

14 May 2018

author name string

Jonathan Friedberg

1

1 reference

14 May 2018

Eric Jacobsen

2

1 reference

14 May 2018

Jeffrey Kutok

4

1 reference

14 May 2018

Olivier Munoz

5

1 reference

14 May 2018

Vassiliki Boussiotis

6

1 reference

14 May 2018

Hazel Reynolds

7

1 reference

14 May 2018

David Fisher

8

1 reference

14 May 2018

Agnieszka Szot

9

1 reference

14 May 2018

Annick Van Den Abbeele

10

1 reference

14 May 2018

Arnold Freedman

11

1 reference

14 May 2018

publication date

1 May 2008

1 reference

14 May 2018

published in

Leukemia & Lymphoma

1 reference

14 May 2018

volume

49

1 reference

14 May 2018

issue

5

1 reference

14 May 2018

page(s)

902-909

1 reference

14 May 2018

New treatment options have changed the survival of patients with follicular lymphoma

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Follicular dendritic cells in non-Hodgkin lymphomas: Localisation, characterisation and pathophysiological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Proliferation of non-Hodgkin-lymphoma lymphocytes in vitro is dependent upon follicular dendritic cell interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Functional effects of TNF and lymphotoxin alpha1beta2 on FDC-like cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190801950033

10.1080/10428190801950033

21 January 2018

Identifiers

DOI

1 reference

14 May 2018

release_zs453v2wgjg4fc7zh4h2hbcxpq

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/zs453v2wgjg4fc7zh4h2hbcxpq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

14 May 2018